Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery

@article{Lane2007NepafenacOS,
  title={Nepafenac ophthalmic suspension 0.1\% for the prevention and treatment of ocular inflammation associated with cataract surgery},
  author={Stephen S. Lane and Satish S. Modi and Robert P Lehmann and Edward Holland},
  journal={Journal of Cataract and Refractive Surgery},
  year={2007},
  volume={33},
  pages={53–58}
}
PURPOSE: To determine whether nepafenac ophthalmic suspension 0.1% decreases the incidence and severity of inflammation and pain after cataract surgery with posterior chamber intraocular lens implantation. SETTING: Twenty‐one ophthalmology clinics in the United States. METHODS: A randomized double‐blind vehicle‐controlled trial was conducted in which adult patients were randomly assigned to receive nepafenac 0.1% or vehicle beginning 1 day before surgery and continuing on the day of surgery… 
Nepafenac 0.1% plus dexamethasone 0.1% versus dexamethasone alone: Effect on macular swelling after cataract surgery
TLDR
The combination of topical nepafenac and steroid treatment reduced subclinical macular swelling and inflammation as well as subjective complaints, indicating it is an efficient antiinflammatory regimen after cataract surgery.
Study nepafenac 0.1% suspension in treating postoperative inflammation and ocular pain associated with surgery of cataract patients
TLDR
Nepafenac ophthalmic suspension is a nonsteroidal anti inflammatory drug effective in the prevention of postoperative inflammation and ocular pain associated with cataract surgery.
Once‐daily nepafenac ophthalmic suspension 0.3% to prevent and treat ocular inflammation and pain after cataract surgery: Phase 3 study
TLDR
Once‐daily nepafenac 0.3% was well tolerated and had a safety profile comparable to that of nepafe 0.1% 3 times daily for prevention and treatment of ocular inflammation and pain following cataract surgery.
Phase II placebo-controlled study of nepafenac ophthalmic suspension 0.1% for postoperative inflammation and ocular pain associated with cataract surgery in Japanese patients
  • J. Numaga
  • Medicine
    Journal of ophthalmic inflammation and infection
  • 2011
TLDR
Nepafenac ophthalmic suspension is a nonsteroidal anti-inflammatory drug effective in the prevention of postoperative inflammation and ocular pain associated with cataract surgery.
Analgesic and anti-inflammatory effectiveness of nepafenac 0.1% for cataract surgery
TLDR
The anti-inflammatory efficacy of nepafenac 0.1% is better than that of placebo; it is also more comfortable and at least equal to ketorolac 0 .5% in the prevention and treatment of postoperative ocular pain and inflammation.
Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification
TLDR
Both bromfenac ophthalmic solution 0.07% and nepafenac 0.3% produced positive and similar clinical outcomes with regard to ETDRS visual acuity post-cataract surgery when dosed using identical regimens.
Comparison of bromfenac 0.09% QD to nepafenac 0.1% TID after cataract surgery: pilot evaluation of visual acuity, macular volume, and retinal thickness at a single site
TLDR
Postoperative measurements of macular volume and retinal thickness of bromfenac subjects showed a trend toward improved vision, less retinal thickening, and more stable macular volumes overall, which resulted in positive clinical outcomes of Early Treatment Diabetic Retinopathy Study visual acuities.
0.1% Nepafenac reduces pain and increases patient comfort during cataract surgery.
TLDR
0.1% nepafenac reduces pain of patients who undergone routine clear corneal phacoemulsification with topical anesthesia and may increase patient comfort during the surgery when used preoperatively.
Role of Topical Nepafenac and Topical Dexamethasone in Postoperative Inflammation after Cataract Surgery: A Comparative Study.
TLDR
Nepafenac is equally effective as topical steroid and can safely be used in routine postoperative inflammation after uncomplicated cataract surgery.
Comparison between 0.1% Nepafenac and 1% Prednisolone Eye Drop in Postoperative Management Following Micro-incisional Cataract Surgery
TLDR
Nepafenac is equally effective and non-inferior to prednisolone acetate in suppression and prevention of inflammation in postoperative period of micro-incisional cataract surgery.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 19 REFERENCES
Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery.
TLDR
Ketorolac tromethamine 0.5% ophthalmic solution was significantly more effective than vehicle in the treatment of moderate or greater ocular inflammation following routine cataract surgery, while being as safe as vehicle.
Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: a randomized, vehicle-controlled clinical trial.
TLDR
Ketorolac tromethamine 0.5% ophthalmic solution is safe and provides substantial anti-inflammatory activity in the treatment of moderate to severe anterior segment inflammation developing after cataract surgery and intraocular lens implantation.
Efficacy of preoperative versus postoperative ketorolac tromethamine 0.5% in reducing inflammation after cataract surgery
TLDR
There was no difference in the efficacy of administering ketorolac 30 minutes preoperatively versus 1 day postoperatively in reducing inflammation after cataract surgery.
The effect of ketorolac tromethamine solution 0.5% in reducing postoperative inflammation after cataract extraction and intraocular lens implantation.
TLDR
This study supported previous studies that suggested ketorolac tromethamine ophthalmic solution 0.5% was effective and safe as a nonsteroidal anti-inflammatory agent for topical use after ECCE and IOL implantation.
Comparative effects of ketorolac 0.5% or diclofenac 0.1% ophthalmic solutions on inflammation after cataract surgery.
TLDR
This study shows diclofenac sodium 0.1% and ketorolac tromethamine 0.5% ophthalmic solutions are equally effective and safe for the control of postoperative inflammation after uncomplicated cataract surgery performed by phacoemulsification followed by the implantation of a foldable intraocular lens.
Comparison of ketorolac tromethamine 0.5% and rimexolone 1% to control inflammation after cataract extraction: Prospective randomized double‐masked study
TLDR
Ketorolac tromethamine 0.5% was as effective as rimexolone 1% in reducing inflammation after cataract surgery and is suggested to be a safe and effective antiinflammatory alternative to steroids afterCataract extraction.
A comparison of topical diclofenac with prednisolone for postcataract inflammation.
TLDR
In the dosage used, diclofenac was as effective an anti-inflammatory agent for uncomplicated post-cataract inflammation as prednisolone.
A comparison of topical non-steroidal anti-inflammatory drugs to steroids for control of post cataract inflammation.
TLDR
Diclofenac sodium was as effective an anti-inflammatory agent for postoperative inflammation as prednisolone acetate for patients undergoing phacoemulsification with posterior chamber intraocular lens implants.
The effect of ketorolac tromethamine in reducing postoperative inflammation: double-mask parallel comparison with dexamethasone.
TLDR
Kentorolac solution was as effective as dexamethasone solution in suppressing postoperative inflammation after cataract surgery as measured by fluorophotometry and as observed by slit-lamp examinations.
Comparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: Prospective randomized double‐masked study
TLDR
The results suggest that ketorolac tromethamine 0.5% is a safe and effective antiinflammatory alternative to steroids after cataract extraction and loteprednol etabonate ophthalmic suspension 0.
...
1
2
...